TY - JOUR
AU - Gladwin, Mark T.
AB - ContextThe efficient sequestration of hemoglobin by the red blood cell membrane and the presence of multiple hemoglobin clearance mechanisms suggest a critical need to prevent the buildup of this molecule in the plasma. A growing list of clinical manifestations attributed to hemoglobin release in a variety of acquired and iatrogenic hemolytic disorders suggests that hemolysis and hemoglobinemia should be considered as a novel mechanism of human disease.Evidence AcquisitionPertinent scientific literature databases and references were searched through October 2004 using terms that encompassed various aspects of hemolysis, hemoglobin preparations, clinical symptoms associated with plasma hemoglobin, nitric oxide in hemolysis, anemia, pulmonary hypertension, paroxysmal nocturnal hemoglobinuria, and sickle-cell disease.Evidence SynthesisHemoglobin is released into the plasma from the erythrocyte during intravascular hemolysis in hereditary, acquired, and iatrogenic hemolytic conditions. When the capacity of protective hemoglobin-scavenging mechanisms has been saturated, levels of cell-free hemoglobin increase in the plasma, resulting in the consumption of nitric oxide and clinical sequelae. Nitric oxide plays a major role in vascular homeostasis and has been shown to be a critical regulator of basal and stress-mediated smooth muscle relaxation and vasomotor tone, endothelial adhesion molecule expression, and platelet activation and aggregation. Thus, clinical consequences of excessive cell-free plasma hemoglobin levels during intravascular hemolysis or the administration of hemoglobin preparations include dystonias involving the gastrointestinal, cardiovascular, pulmonary, and urogenital systems, as well as clotting disorders. Many of the clinical sequelae of intravascular hemolysis in a prototypic hemolytic disease, paroxysmal nocturnal hemoglobinuria, are readily explained by hemoglobin-mediated nitric oxide scavenging.ConclusionA growing body of evidence supports the existence of a novel mechanism of human disease, namely, hemolysis-associated smooth muscle dystonia, vasculopathy, and endothelial dysfunction.Hemoglobin is a highly conserved molecule found in species ranging from single-cell organisms to mammals, but the role of hemoglobin in different organisms varies. While hemoglobin in bacteria functions as a nitric oxide sump by oxidation of nitric oxide to nitrate,hemoglobin functions to remove oxygen in nematodes, a critical task for anaerobes.By contrast, in mammals, hemoglobin primarily serves a respiratory function in the delivery of oxygen and removal of carbon dioxide. Based on the recent discovery that nitric oxide is a critical regulator of vasodilation and vascular homeostasis, the interactions of nitric oxide with hemoglobin in mammals has drawn increasing interest. Because the reaction of nitric oxide with the vast amounts of intravascular oxyhemoglobin (16 g/dL) is fast (107M-1s−1) and irreversible, it would be expected that nitric oxide produced by endothelium would be immediately scavenged by hemoglobin and would therefore be incapable of paracrine diffusion from endothelium to vascular smooth muscle.However, the ability of hemoglobin to react with nitric oxide produced by endothelium is limited by compartmentalization of hemoglobin inside the erythrocyte.Thus, the evolution of the erythrocyte may be considered as a mechanism of reducing toxicity while ensuring separation of the critical respiratory transport machinery needed for efficient oxygen delivery from the endothelium. Moreover, multiple systems have evolved to control the level of cell-free hemoglobin in the plasma during normal physiological hemolysis, presumably to curtail the deleterious effects of plasma hemoglobin on nitric oxide bioavailability and endothelial function.During intravascular hemolysis, cell-free plasma hemoglobin may overwhelm homeostatic systems in place to remove it.Hemolytic conditions with substantial intravascular hemolysis include paroxysmal nocturnal hemoglobinuria (PNH), sickle-cell disease (SCD), thalassemias, hereditary spherocytosis and stomatocytosis, microangiopathic hemolytic anemias, pyruvate kinase deficiency, ABO mismatch transfusion reaction, paroxysmal cold hemoglobinuria, severe idiopathic autoimmune hemolytic anemia, infection-induced anemia, malaria, cardiopulmonary bypass, mechanical heart valve–induced anemia, and chemical-induced anemias. Although the various hemolytic diseases each have unique symptoms, they often share hemoglobinemia-related sequelae. In addition, observations from the clinical administration of artificial, purified, and recombinant hemoglobin solutions have provided further support for the causal relationship between excess cell-free hemoglobin in the bloodstream, symptoms, and cardiovascular events.Nitric oxide scavenging by excess plasma hemoglobin has been implicated in various clinical manifestations of intravascular hemolysis. Nitric oxide is a regulator of smooth muscle tone and platelet activation, and reductions in nitric oxide plasma levels lead to smooth muscle dystonias, including hypertension, gastrointestinal contractions, and erectile dysfunction, as well as clot formation.Hemoglobin also exerts direct cytotoxic, inflammatory, and pro-oxidant effects that adversely affect endothelial function.EVIDENCE ACQUISITIONMultiple searches were performed with the New England Research Application Center and PubMed through October 2004, including various combinations of the following key search terms: hemoglobin, recombinant, cell-free, stroma-free, artificial,heme, hemolysis, marker, lactate dehydrogenase, LDH,anemia, pulmonary hypertension, abdominal, abdomen, pain, erectile dysfunction, dysphagia, smooth muscle, nitric oxide, paroxysmal nocturnal hemoglobinuria, and sickle-cell disease. References cited in textbooks or articles were also used in some cases. Plasma hemoglobin concentrations are reported throughout this review in terms of hemoglobin tetramer. Because each tetramer contains 4 heme groups, hemoglobin can react with and inactivate 4 nitric oxide molecules.EVIDENCE SYNTHESISThe Removal of Hemoglobin During Intravascular HemolysisWhen red blood cells (RBCs) are destroyed within the vascular compartment, hemoglobin escapes into the plasma, dimerizes, and is rapidly bound by the serum protein haptoglobin. The haptoglobin-hemoglobin complex exposes a neoepitope that is recognized by the hemoglobin scavenger receptor, CD163 on the surface of monocytes/macrophages, which binds the complex with high affinity and mediates haptoglobin-hemoglobin endocytosis and degradation.Since haptoglobin is not recycled, formation of large amounts of haptoglobin-hemoglobin complexes leads to rapid haptoglobin depletion. Thus, in severe hemolytic diseases such as PNH and SCD, serum haptoglobin is typically undetectable.Ferrous heme (FeII), the oxygen-binding component of hemoglobin, can be oxidized to ferric heme (FeIII), which is then released from hemoglobin and binds with high affinity to a plasma glycoprotein, hemopexin. Heme bound to hemopexin is degraded in a series of enzymatic steps in the liver. Heme oxygenase 1 (HO-1) subsequently breaks down the pro-oxidant and pro-inflammatory heme into carbon monoxide, biliverdin, and iron. Carbon monoxide has vasodilatory, antiproliferative, anti-inflammatory, and antioxidant properties,while biliverdin is an antioxidant that is converted by biliverdin reductase to bilirubin.Biliverdin reductase itself has catalytic antioxidant properties.The heme-derived oxidant iron is directly sequestered and inactivated by ferritin.Additionally, haptoglobin-hemoglobin binding to CD163 signals anti-inflammatory IL-10 and HO-1 induction in circulating monocytes.Thus, the antioxidant, anticoagulant, antiproliferative, and vasodilating effects of the CD163/HO-1/biliverdin reductase systems likely represent an evolved compensation for the nitric oxide scavenging, vasoconstrictive, proliferative, inflammatory, and pro-oxidant effects of extracellular hemoglobin, heme, and heme-iron.When the capacity of these scavenging mechanisms has been saturated during acute or chronic hemolysis, levels of hemoglobin and heme increase in the plasma and urine. Plasma hemoglobin has the ability to scavenge nitric oxide while heme possesses multiple proinflammatory and pro-oxidant properties.Hemolysis Causes Local and Systemic Nitric Oxide Deficiency Through the Release of Hemoglobin in PlasmaNitric oxide reacts with hemoglobin in an extremely fast and irreversible reaction (107M-1s-1) that produces an inactive oxidation product nitrate (NO3) and methemoglobin.The speed and irreversibility of this reaction is such that very little hemoglobin can completely inhibit endothelial nitric oxide and produce endothelial dysfunction. For example, 0.01 g/dL of hemoglobin is sufficient to completely inhibit aortic ring dilation on exposure to acetylcholine.Under normal physiological conditions, the reaction rate of nitric oxide and hemoglobin is severely limited by approximately 600-fold due to multiple diffusional barriers to nitric oxide around the RBC membrane and along the endothelium in laminar flowing blood.According to this model, vascular homeostasis is dependent on the compartmentalization or physical separation of hemoglobin from endothelium.During intravascular hemolysis, this separation and the diffusional barriers are disrupted, resulting in efficient nitric oxide scavenging and endothelial dysfunction.Haptoglobin can bind approximately 0.07 to 0.15 g/dL of hemoglobin depending on the haptoglobin allotype.Once the capacity of this hemoglobin-scavenging protein is exceeded, consumption of endogenous nitric oxide intensifies. Plasma hemoglobin levels in patients with PNH are commonly in the range of 0.05 to 0.2 g/dL and can exceed 1.0 g/dL during severe hemolytic episodes.Similarly, plasma hemoglobin levels range from 0.001 to 0.033 g/dL in SCD and can exceed 0.041 g/dL during vaso-occlusive crisis.Because the haptoglobin/hemoglobin complex is degraded in the liver, the occurrence of steady state intravascular hemolysis in diseases such as PNH and SCD typically generates sufficient plasma hemoglobin to completely deplete haptoglobin. It has been shown that quantities of plasma hemoglobin greater than 0.01 g/dL can potently inhibit nitric oxide–dependent vasodilation in vivo.In vitro consumption of nitric oxide in patients with SCD is highly correlated with measured plasma hemoglobin levels (R = 0.92), and immunodepletion of hemoglobin from plasma eliminates the ability of the plasma to consume nitric oxide.Consistent with an in vivo effect of elevated circulating plasma hemoglobin on endothelial function, patients with SCD exhibit blunted vasodilatory responses to infusions of the direct-acting nitric oxide donor sodium nitroprusside.In fact, patients with plasma hemoglobin levels higher than 0.01 g/dL have an 80% reduction in nitric oxide–dependent blood flow responses. Moreover, nitroglycerin-induced vasodilation is impaired in SCD patients,and diminished vasomotor response to nitric oxide donors is observed in transgenic sickle-cell mice.These mice also exhibit systemic resistance to nitric oxide donors, which correlates with hemolytic rate and plasma hemoglobin levels.While there is clearly a state of nitric oxide–mediated resistance in SCD patients and transgenic sickle-cell mouse models, overall blood flow and cardiac output are high in the face of the associated anemia. This increase in cardiac output in response to anemia appears to be mediated by up-regulation of non–nitric oxide vasodilators such as prostacyclin and endothelium-derived hyperpolarizing factor. This is illustrated in SCD patients by normal or high basal blood flow responses to acetylcholine, an endothelium-dependent vasodilator, which is not affected by simultaneous nitric oxide synthase inhibition (L-NMMA).The hypothesis of a compensatory increase in non–nitric oxide vasodilators was recently confirmed by Kaul and colleagues who demonstrated that transgenic mice expressing exclusively human hemoglobin S exhibit complete resistance to nitric oxide–mediated vasodilation accompanied by an increase in cyclooxygenase 2 (COX-2) levels and non–nitric oxide-dependent blood flow.In addition to hemoglobin decompartmentalization and nitric oxide scavenging, hemolysis also releases erythrocyte arginase, an enzyme that converts L-arginine, the substrate for nitric oxide synthesis, to ornithine, thereby further reducing the systemic availability of nitric oxide.Consistent with this observation, the arginine-to-ornithine ratio decreases significantly as pulmonary pressures increase in SCD patients.The biological effects of nitric oxide and its removal during intravascular hemolysis are depicted in the Figure. We propose that the release of hemoglobin during intravascular hemolysis results in excessive consumption of nitric oxide, subsequent reduction in guanylate cyclase activity, smooth muscle contraction, vasoconstriction, and platelet activation/aggregation.Figure.Pathobiological Effects of Cell-Free Plasma Hemoglobin and Nitric Oxide (NO) Depletion During Intravascular HemolysisDuring intravascular hemolysis, hemoglobin is released into the plasma where it is normally cleared by the hemoglobin scavengers haptoglobin, CD163, and hemopexin. Haptoglobin-hemoglobin complexes bind to CD163 on the surface of macrophages/monocytes initiating endocytosis and degradation of the complex. Hemoglobin also releases ferric heme on oxidation, which is bound by hemopexin and degraded by hepatocytes in the liver. Excessive hemolysis saturates and depletes these hemoglobin removal systems and leads to a buildup of hemoglobin and heme in the plasma. Plasma hemoglobin and heme mediate direct proinflammatory, proliferative, and pro-oxidant effects on vessel endothelial cells. NO is normally generated from L-arginine in vessel endothelial cells by the enzyme nitric oxide synthase (NOS). NO maintains smooth muscle relaxation and inhibits platelet activation and aggregation, thereby regulating vessel tone and promoting organ system homeostasis. During intravascular hemolysis, NO availability can be severely limited by its reaction with oxyhemoglobin (NO scavenging) and by the breakdown of the substrate for NO synthesis, L-arginine, by the red cell enzyme arginase, despite elevated levels of NOS (decreased NO synthesis). NO depletion results in decreased activation of guanylate cyclase, an enzyme required for the generation of cyclic guanine monophosphate (cGMP). Decreased cGMP levels disrupt regulation of smooth muscle tone resulting in dystonias, including systemic and pulmonary hypertension, erectile dysfunction, dysphagia, and abdominal pain. Decreased cGMP levels through the depletion of NO can also lead to platelet activation and aggregation, promoting clot formation. GTP indicates guanosine 5’-triphosphate.The systemic removal of nitric oxide has been shown to contribute to clinical morbidities, including severe esophageal spasm and dysphagia, abdominal pain, erectile dysfunction, and thrombosis.In addition, systemic release of hemoglobin is associated with pulmonary and systemic hypertension,decreased organ perfusion, and increased mortality.Plasma hemoglobin and its breakdown product heme can also directly activate endothelial cells and further promote inflammation and coagulation.Plasma Hemoglobin Causes Dose-Dependent Increases in Adverse Clinical Signs and SymptomsStroma-free hemoglobin, cross-linked human or bovine hemoglobin, purified human hemoglobin, or recombinant human hemoglobin preparations have been administered to patients, human volunteers, and animals. As summarized in the Table, intravascular plasma hemoglobin is associated with a dose-dependent increase in adverse clinical signs and symptoms, including hemoglobinuria, abdominal pain, sternal pain, esophageal spasm, and dysphagia, as well as increases in blood pressure, platelet activation, creatine kinase level, and mortality.Table.Clinical Signs and Symptoms Associated With the Administration of Hemoglobin SolutionsSourceModelHemoglobin DoseEstimated Blood Hemoglobin Level*Clinical Signs and Symptomsg/dL&mgr;MPrzybelski et al,199624 Healthy adult volunteers25 mg/kg 50 mg/kg 100 mg/kg0.05 0.10 0.207.8 15.6 31.2Abdominal pain and sternal pain; increased CK level; increased BP with high doseSavitsky et al,197810 Healthy adult men16 g0.2335.9Hemoglobinuria; abdominal pain; increased BP; creatinine clearance reductionSloan et al,1999112 Patients with traumatic hemorrhagic shock50-100 g0.71-1.42110.9-221.8Increased mortalityCarmichael et al,200042 Healthy adult male volunteers1.7-42 g0.02-0.603.7-93.7Hemoglobinuria moderate >0.10 g/dL; increased BP over 0.05 g/dL with increased duration over 0.10 g/dL; abdominal pain and dysphagia: <0.40 g/dL (12/32 mild); >0.40 g/dL (10/10 moderate-severe); dysphagia relieved by smooth muscle relaxantsMurray et al,19959 Volunteers0.11-0.15 g/kg0.11-0.1517.1-23.4Dose-dependent increase in duration of esophageal contractions; dysphagia and CP: 0.15 g/dL (4/6 participants)Lamy et al,2000209 Postcardiac bypass patients25 g 50 g 75 g0.36 0.71 1.0856.2 110.9 168.7Hemoglobinuria; significant increase in BP, SVR, PVR after 0.36 g/dL; increased pancreatic enzyme levels; jaundiceViele et al, 199748 Healthy adult male volunteers0.015-0.32 g/kg0.02-0.322.3-50.0Hemoglobinuria; dose-dependent gastrointestinal symptoms including abdominal pain and dysphagia: 0.02-0.11 g/dL (6/16 participants), 0.15-0.22 g/dL (11/12 participants), 0.25-0.32 g/dL (6/6 participants); prophylactic smooth muscle relaxants required in 2 highest dose groups; increased amylase/lipase levels; transient modest increase in BP and heart rateLamuraglia et al,200072 Vascular surgery patients60 g0.86134.3Significant increases in BP and BUN; trends for increases in creatinine and amylase levelsSaxena et al,199985 Stroke patients25 mg/kg 50 mg/kg 100 mg/kg0.03 0.05 0.103.9 7.8 15.6Hemoglobinuria; jaundice at 0.10 g/dL; dose-dependent increase in BP durationOlsen et al, 199666 Rats CEA model0.88 g/kg0.6296.871% Increased platelet activation; 26% increase in BPAbbreviations: BP, blood pressure; BUN, blood urea nitrogen; CEA, carotid endarterectomy; CK, creatine kinase; CP, chest pain; PVR, pulmonary vascular resistance; SVR, systemic vascular resistance.*All blood hemoglobin values are estimates except for those of Przybelski et al,which reflect actual plasma values; calculations assume a weight of 70 kg and a blood volume of 7 L.Hemoglobinuria and Renal Dysfunction. Hemoglobinuria is one of the most prominent clinical signs of excessive intravascular hemolysis and is commonly associated with the administration of hemoglobin solutions.Plasma hemoglobin is normally filtered through the glomerulus and actively reabsorbed in proximal tubule cells where it is catabolized with release of iron in the form of hemosiderin. When the kidney’s reabsorption capacity is exceeded, clinically significant hemoglobinuria occurs. Acute renal failure may occur during severe episodes of hemoglobinuria.Persistent severe hemoglobinuria is also associated with substantial proximal tubule hemosiderin deposition, Fanconi syndrome (defective renal reabsorption of small molecules leading to hyperaminoaciduria, glycosuria, hyperphosphaturia, and bicarbonate and water loss), and chronic renal failure.Gastrointestinal Dystonias and Pain. Administration of hemoglobin preparations to healthy human volunteers is associated with dose-dependent gastrointestinal symptoms, including abdominal pain, esophageal spasms, and dysphagia.Increasing doses of recombinant hemoglobin result in increases in the duration of esophageal contractions.Further, acute episodes of intravascular hemolysis in patients undergoing long-term dialysis with plasma hemoglobin levels ranging from approximately 0.3 to 2.1 g/dL have also been associated with abdominal pain.Hemoglobin-induced esophageal spasms are most likely attributable to nitric oxide consumption, as inhibition of this molecule in healthy human volunteers results in an increase in esophageal peristaltic amplitude and velocity (spasms) and a decrease in gastric distention-triggered transient lower esophageal sphincter relaxation.Consistent with this hypothesis, augmentation of the downstream effect of nitric oxide via inhibition of phosphodiesterase type 5 (PDE5) with sildenafil relieves spasms in patients with esophageal motor disorders.Vasoconstriction and Systemic and Pulmonary Hypertension. The administration of cell-free hemoglobin solutions to healthy volunteers and patients is commonly associated with a dose-dependent increase in systolic and diastolic blood pressure,which is reversed by the administration of the nitric oxide donor, sodium nitroprusside, confirming the importance of nitric oxide scavenging in vasoregulation.Plasma hemoglobin and erythrocytes also augment hypoxic pulmonary vasoconstriction by scavenging nitric oxide, with plasma hemoglobin demonstrating an approximate 1000-fold greater nitric oxide scavenging potency in these models.Pulmonary arterial hypertension is an increasingly recognized complication of chronic hereditary and acquired hemolytic anemias, including SCD,thalassemia intermedia and major,PNH,hereditary spherocytosis and stomatocytosis,microangiopathic hemolytic anemias,and pyruvate kinase deficiency.There are a number of pathophysiological features shared by these disparate disorders, including intravascular hemolysis, iron overload, a propensity toward thrombosis, and surgical or autosplenectomy.In a recent study of 195 adult patients with SCD, 32% had mild to severe pulmonary hypertension. Markers of hemolysis, including anemia, bilirubin, lactate dehydrogenase (LDH), and aspartate aminotransferase (but not liver-specific alanine aminotransferase), were associated with pulmonary hypertension.In addition to limiting nitric oxide bioavailability via hemoglobin-based nitric oxide scavenging and dysregulated arginine metabolism, hemolysis is associated with activation of downstream adhesion, prothrombotic, and pro-oxidant pathways that may further contribute to endothelial dysfunction and vasculopathy.Other mechanisms may also contribute to the development of pulmonary hypertension, including chronic thromboembolism and in situ thrombosis, asplenia, pulmonary fibrosis, liver cirrhosis secondary to iron overload and hepatitis C, and induction of hypoxia-inducible factor 1α–dependent factors such as vascular endothelial growth factor, endothelin 1, and erythropoietin.Thrombosis and Platelet Activation. Excessive plasma hemoglobin may contribute to platelet activation and thrombosis. The infusion of cross-linked hemoglobin increases platelet aggregation and adhesion in vivo on prothrombotic surfaces such as an injured vessel wall.Additionally, administration of heme in healthy volunteers is associated with thrombophlebitis, demonstrating that heme can cause vascular inflammation followed by vascular obstruction in vivo.Interestingly, the addition of cell-free hemoglobin to human serum at concentrations of 0.2 to 2.0 g/dL causes a dose-dependent inhibition of the metalloprotease ADAMTS13, an enzyme critical in limiting platelet thrombus formation.The major untoward effects of plasma hemoglobin on platelet function are most likely mediated by the scavenging of nitric oxide. Nitric oxide has been shown to inhibit platelet aggregation, induce disaggregation of aggregated platelets, and inhibit platelet adhesion through increasing cyclic guanine monophosphate (cGMP) levels.In fact, nitric oxide donor drugs (S-nitrothiols) that increase systemic levels of nitric oxide have been shown to inhibit platelet aggregation.Conversely, nitric oxide scavenging by hemoglobin or the reduction of nitric oxide generation by the inhibition of arginine metabolism results in an increase in platelet aggregation.Nitric oxide interacts with components of the coagulation cascade to downregulate clot formation. For example, nitric oxide has been shown to chemically modify and inhibit factor XIII, which suggests that nitric oxide deficiency would enhance clot stability and reduce clot dissolution.In animal models, reduction of nitric oxide causes increases in fibrin split products and thrombin-antithrombin complexes leading to significant fibrin deposition and thrombus formation.Moreover, in a patient with L-arginine deficiency, reduced nitric oxide production is associated with increased thrombin-antithrombin complexes and fibrin split products, while reversal of nitric oxide deficiency with L-arginine causes a reduction in intravascular coagulopathy.Erectile Dysfunction. Hemoglobin release during intravascular hemolysis has been implicated in the pathogenesis of erectile dysfunction in patients with PNH, presumably through the scavenging of nitric oxide.It has been well established that local nitric oxide deficiency due to decreased synthesis, impaired release, or premature destruction is one of the factors responsible for erectile dysfunction. The capacity of PDE5 inhibitors such as sildenafil to improve erectile dysfunction via the accumulation of cGMP is dependent on the availability of nitric oxide.Inflammation and Oxidation. Plasma hemoglobin and heme may possess inflammatory properties. The presence of large amounts of vascular heme results in inflammatory infiltrates in various organs in mice and induction of neutrophil activation and migration in vitro.Heme stimulates the expression of the adhesion molecules ICAM-1 (intracellular adhesion molecule 1), VCAM-1 (vascular cell adhesion molecule 1), and E-selectin on endothelial cells in vitro.Heme and hemoglobin blood substitutes are associated with significant increases in vascular permeability.Plasma hemoglobin promotes formation of the biologically hazardous hydroxyl-radical, a process that may be regulated by the hemoglobin scavenger haptoglobin.Many of the proinflammatory effects of plasma hemoglobin and heme may involve consumption of nitric oxide. Studies have shown that nitric oxide inhibits cytokine-induced induction of VCAM-1, ELAM-1 (endothelial leukocyte adhesion molecule 1), and ICAM-1 resulting in an anti-inflammatory effect.The consumption of nitric oxide by hemoglobin circumvents the anti-inflammatory properties of nitric oxide.Paroxysmal Nocturnal Hemoglobinuria: a Prototypic Disease of Intravascular HemolysisParoxysmal nocturnal hemoglobinuria is an acquired clonal disorder of the hemopoietic stem cell that is characterized by chronic intravascular hemolysis, as indicated by the grossly elevated levels of LDH in almost all patients. Episodes of severe intravascular hemolysis are manifest clinically by hemoglobinuria (the hallmark of PNH) and are also frequently associated with dysphagia, abdominal pain, erectile dysfunction, thrombosis, and disabling fatigue.The biochemical defect underlying PNH occurs in the synthesis of the glycosyl-phosphatidylinositol (GPI) anchor.This glycolipid structure is the means by which many proteins are attached to the plasma membrane. Two GPI-linked proteins missing from PNH cells are the complement regulatory proteins CD55 (also called “decay-accelerating factor”) and CD59 (also called “membrane inhibitor of reactive lysis”). The lack of complement regulation on the PNH RBC surface renders these cells extremely sensitive to complement-mediated lysis resulting in systemic hemoglobin release.Lactate dehydrogenase catalyzes the reversible reduction of pyruvate to lactate by nicotinamide adenine dinucleotide. Red blood cells contain large amounts of LDH, and quantitation of total LDH and hemoglobin in osmotically lysed RBCs shows a near uniform correlation between these parameters in vitro.Lactate dehydrogenase is released into the plasma during hemolysis, and levels of this enzyme are generally elevated in patients with intravascular hemolysis.Elevated levels of LDH are common among PNH patients due to ongoing chronic intravascular hemolysis.Lactate dehydrogenase is accepted as an accurate measure of intravascular hemolytic rate in PNH patients, and resolution of hemolysis in these patients results in an immediate reduction in LDH levels to near normal values.A paroxysm, from which PNH derives its name, occurs when there is a sudden marked increase in the rate of intravascular hemolysis. During such paroxysms, LDH levels can reach more than 25 times that of normal.Paroxysms can be precipitated by events such as infection, drugs, and trauma, or they can occur spontaneously.Paroxysms are characterized by severe bouts of hemoglobinuria, and more than 90% of PNH patients exhibit hemoglobinuria at some point in the disease, with approximately 50% of patients presenting with this clinical sign.During a severe paroxysm, hemoglobin filtered through the kidney can reach sufficient levels to turn the urine black. Severe hemoglobinuria typically lasts 3 to 7 days, but extended episodes can occur. The incidence of hemoglobinuria is increased in patients with a large proportion of PNH blood cells (large PNH clone), as clone size often correlates with the degree of hemolysis.In addition, it is well documented that intense hemoglobinuria during a paroxysm can be associated with acute renal failure.As described above, many organ systems that are innervated by smooth muscle are adversely affected by administration of exogenous hemoglobin preparations, most likely due to the systemic removal of nitric oxide. Similarly, during paroxysms, PNH patients exhibit symptoms that are consistent with smooth muscle perturbation through the release of hemoglobin and nitric oxide scavenging, including abdominal pain, esophageal spasms, and erectile dysfunction.Abdominal pain is experienced by approximately 35% of PNH patients during a paroxysm, and episodes are more common in patients with a large PNH clone.Although thrombosis of the mesenteric venous tree has been implicated in recurrent episodes of abdominal pain,many such cases do not show evidence of thrombosis. Further, abdominal pain usually rapidly resolves when the paroxysm abates, supporting the hypothesis that nitric oxide scavenging causes intestinal dystonia and spasm.Esophageal spasm and dysphagia due to strong peristaltic waves are a common occurrence in PNH patients, with a reported incidence of approximately 23%.Dysphagia in these patients has also been shown to be closely linked to a large PNH clone and hemolysis.Similarly, episodes of dysphagia are most commonly associated with paroxysms and tend to resolve as the hemolysis subsides.Erectile dysfunction occurs in 35% of male patients with PNH and is associated with paroxysms and PNH clone size, although erectile dysfunction can persist beyond hemolytic episodes and in many cases become permanent.Erectile dysfunction in these patients appears to improve with PDE5 inhibitor therapy, as long as macroscopic hemoglobinuria is absent, suggesting a role for nitric oxide scavenging in the pathogenesis (P.H., unpublished data, 2005).Thrombosis is the most common cause of death in PNH patients. In a series of 80 PNH patients, 50% of PNH-related deaths were attributed to venous thrombosis, and approximately 40% of patients experienced thrombosis at some point in the disease.The most frequent types of thrombosis in this study included hepatic, pulmonary, deep, cerebral, and superficial veins, and inferior vena cava. Interestingly, there is a tight correlation between thrombosis and a large PNH clone, and clone size correlates with hemolytic rates.As described above, nitric oxide plays an important role in the maintenance of normal platelet functions through the down-regulation of platelet aggregation and adhesion and the regulation of molecules in the coagulation cascade. Accordingly, the chronic consumption of nitric oxide by plasma hemoglobin has been implicated in the formation of clots in PNH patients. Indeed, thrombotic events such as Budd-Chiari syndrome increase in PNH patients during severe bouts of hemolysis (Wendell F. Rosse, MD, oral communication, August 6, 2003). The lack of the complement regulatory proteins CD55 and CD59 on the surface of PNH platelets, which renders these cells more sensitive to complement-mediated activation,may also contribute to thrombotic tendency in these patients.The relationship between intravascular hemolysis and plasma hemoglobin/nitric oxide–dependent symptoms was recently evaluated with a specific drug intervention in PNH patients. A monoclonal antibody that blocks cleavage of the complement component C5, thereby preventing complement-mediated red cell lysis, was administered to hemolytic PNH patients over a 3-month period.This study demonstrated a dramatic reduction in intravascular hemolysis as LDH levels dropped from 3111 to 594 U/L (normal range, 150-480 U/L; P = .002). Similarly, the rate of hemoglobinuria (paroxysms) was reduced from 2.9 days per patient per month before treatment to 0.12 day per patient per month during treatment (P<.001). Therapeutic resolution of intravascular hemolysis in these patients also resulted in a significant improvement in objectively studied quality of life measurements. Furthermore, clinical assessment of symptoms in these patients prior to drug therapy and after the resolution of hemolysis during treatment showed that symptoms attributed to smooth muscle dystonias, including abdominal pain, dysphagia, and erectile failure, were either completely resolved, or at least dramatically reduced, in most patients.These improvements in quality of life and clinical symptoms occurred despite the observation that total hemoglobin levels were unchanged during treatment, owing to a reduction in hemolytic rate and transfusion requirements. These data suggest that intravascular hemolysis and hemoglobin release mediate much of the symptoms of PNH patients, and further imply that smooth muscle constriction and prothrombotic effects of nitric oxide scavenging by plasma hemoglobin may be involved.CONCLUSIONSIntravascular hemolysis represents a severe pathological condition in a number of vital organ systems. Importantly, in a variety of human volunteer, patient, and animal studies, the presence of cell-free plasma hemoglobin is reproducibly associated with adverse clinical signs and symptoms, including gastrointestinal, cardiovascular, pulmonary, urogenital, hematologic, and renal abnormalities. Further, use of drugs that affect systemic levels of nitric oxide has revealed a strong relationship between homeostasis of these organ systems and the availability of nitric oxide. The demonstration that plasma hemoglobin is an efficient scavenger of nitric oxide, and that hemoglobin levels characteristic of intravascular hemolytic diseases are sufficient to effectively deplete nitric oxide, strongly support a critical role of nitric oxide scavenging in many of the clinical manifestations of hemoglobin release. Indeed, inhibition of complement-mediated hemolysis in PNH results in a reduction in plasma hemoglobin level and resolution of various clinical symptoms, thus demonstrating the close association between hemoglobinemia and these symptoms.These data support the existence of a novel mechanism of human disease, hemolysis-associated smooth muscle dystonia, vasculopathy, and endothelial dysfunction. The definitive link between cell-free plasma hemoglobin, nitric oxide consumption, and symptoms characteristic of intravascular hemolytic diseases is now a topic of intense investigation.Corresponding Authors:Russell P. Rother, PhD, Vice President of Research, Alexion Pharmaceuticals, 352 Knotter Dr, Cheshire, CT 06410 (rotherr@alxn.com); Mark T. Gladwin, MD,Vascular Therapeutics Section, Cardiovascular Branch, NHLBI, Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bldg 10-CRC, Room 5-5140, 10 Center Dr, MSC 1454, Bethesda, MD 20892-1454 (mgladwin@nih.gov).Financial Disclosures: Drs Rother and Bell are employees of and have equity ownership in Alexion Pharmaceuticals; they have also assigned to Alexion Pharmaceuticals their inventions made as employees of the company and have received no royalties from Alexion for those inventions. Dr Gladwin has a collaborative research and development agreement between INO Therapeutics and the Intramural Division of the National Institutes of Health. Dr Hillmen serves as a consultant to Alexion Pharmaceuticals and receives grant support from the company.Acknowledgment:We thank Christopher Mojcik, MD, PhD, Alexion Pharmaceuticals, for intellectual input and critical review of the manuscript.REFERENCESAHausladenAJGowJSStamlerNitrosative stress: metabolic pathway involving the flavohemoglobin.Proc Natl Acad Sci U S A19989514100141059826660MJCrawfordDEGoldbergRole for the Salmonella flavohemoglobin in protection from nitric oxide.J Biol Chem199827312543125479575213PRGardnerAMGardnerLAMartinALSalzmanNitric oxide dioxygenase: an enzymic function for flavohemoglobin.Proc Natl Acad Sci U S A19989510378103839724711DMMinningAJGowJBonaventuraAscaris haemoglobin is a nitric oxide-activated “deoxygenase.”Nature199940149750210519555ANSchechterMTGladwinHemoglobin and the paracrine and endocrine functions of nitric oxide.N Engl J Med20033481483148512686706JSOlsonEWFoleyCRoggeALTsaiMPDoyleDDLemonNO scavenging and the hypertensive effect of hemoglobin-based blood substitutes.Free Radic Biol Med20043668569714990349JTCoinJSOlsonThe rate of oxygen uptake by human red blood cells.J Biol Chem197925411781190762123XLiuMJMillerMSJoshiHSadowska-KrowickaDAClarkJRLancasterJrDiffusion-limited reaction of free nitric oxide with erythrocytes.J Biol Chem199827318709187139668042JCLiaoTWHeinMWVaughnKTHuangLKuoIntravascular flow decreases erythrocyte consumption of nitric oxide.Proc Natl Acad Sci U S A1999968757876110411948IATabbaraHemolytic anemias: diagnosis and management.Med Clin North Am1992766496681578962JPSavitskyJDocziJBlackJDArnoldA clinical safety trial of stroma-free hemoglobin.Clin Pharmacol Ther1978237380618711FJCarmichaelACAliJACampbellA phase I study of oxidized raffinose cross-linked human hemoglobin.Crit Care Med2000282283229210921554MLLamyEKDailyJFBrichantRandomized trial of diaspirin cross-linked hemoglobin solution as an alternative to blood transfusion after cardiac surgery. The DCLHb Cardiac Surgery Trial Collaborative Group.Anesthesiology20009264665610719942MKVieleRBWeiskopfDFisherRecombinant human hemoglobin does not affect renal function in humans: analysis of safety and pharmacokinetics.Anesthesiology1997868488589105229RSaxenaADWijnhoudHCartonControlled safety study of a hemoglobin-based oxygen carrier, DCLHb, in acute ischemic stroke.Stroke19993099399610229733JAMurrayALedlowJLaunspachDEvansMLovedayJLConklinThe effects of recombinant human hemoglobin on esophageal motor functions in humans.Gastroenterology1995109124112487557091RJPrzybelskiEKDailyJCKisickiCMattia-GoldbergMJBoundsWAColburnPhase I study of the safety and pharmacologic effects of diaspirin cross-linked hemoglobin solution.Crit Care Med199624199320008968267GMLamuragliaPJO&apos;HaraWHBakerThe reduction of the allogenic transfusion requirement in aortic surgery with a hemoglobin-based solution.J Vasc Surg20003129930810664499SMErhartDJColePMPatelJCDrummondKEBurhopEffect of alpha-alpha diaspirin crosslinked hemoglobin (DCLHb) on the potency of sodium nitroprusside and nitroglycerine to decrease blood pressure in rats: a dose-response study.Artif Cells Blood Substit Immobil Biotechnol20002838539611009111SDeemJUKimBNManjulaEffects of S-nitrosation and cross-linking of hemoglobin on hypoxic pulmonary vasoconstriction in isolated rat lungs.Circ Res20029162663212364391ROCannonIIIANSchechterJAPanzaEffects of inhaled nitric oxide on regional blood flow are consistent with intravascular nitric oxide delivery.J Clin Invest200110827928711457881MTGladwinVSachdevMLJisonPulmonary hypertension as a risk factor for death in patients with sickle cell disease.N Engl J Med200435088689514985486VMMoyoGLMukhinaESGarrettRABrodskyNatural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays.Br J Haematol200412613313815198744MWRadomskiRMPalmerSMoncadaEndogenous nitric oxide inhibits human platelet adhesion to vascular endothelium.Lancet19872105710582889967SBOlsenDBTangMRJacksonERGomezBAyalaBMAlvingEnhancement of platelet deposition by cross-linked hemoglobin in a rat carotid endarterectomy model.Circulation1996933273328548906ASchaferFWiesmannSNeubauerMEigenthalerJBauersachsKMChannonRapid regulation of platelet activation in vivo by nitric oxide.Circulation20041091819182215066953FAWagenerAEggertOCBoermanHeme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase.Blood2001981802181111535514RLNagelQHGibsonThe binding of hemoglobin to haptoglobin and its relation to subunit dissociation of hemoglobin.J Biol Chem197124669735541775MKristiansenJHGraversenCJacobsenIdentification of the haemoglobin scavenger receptor.Nature200140919820111196644MLJisonPJMunsonJJBarbBlood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease.Blood200410427028015031206LEOtterbeinBSZuckerbraunMHagaCarbon monoxide suppresses arteriosclerotic lesions associated with chronic graft rejection and with balloon injury.Nat Med2003918319012539038TPresteraPTalalayJAlamYIAhnPJLeeAMChoiParallel induction of heme oxygenase-1 and chemoprotective phase 2 enzymes by electrophiles and antioxidants: regulation by upstream antioxidant-responsive elements (ARE).Mol Med199518278378612205SWRyterLEOtterbeinDMorseAMChoiHeme oxygenase/carbon monoxide signaling pathways: regulation and functional significance.Mol Cell Biochem2002234-23524926312162441DEBarananoMRaoCDFerrisSHSnyderBiliverdin reductase: a major physiologic cytoprotectant.Proc Natl Acad Sci U S A200299160931609812456881TWSedlakSHSnyderBilirubin benefits: cellular protection by a biliverdin reductase antioxidant cycle.Pediatrics20041131776178215173506DASearsDisposal of plasma heme in normal man and patients with intravascular hemolysis.J Clin Invest1970495144188269PPhilippidisJCMasonBJEvansHemoglobin scavenger receptor CD163 mediates interleukin-10 release and heme oxygenase-1 synthesis: antiinflammatory monocyte-macrophage responses in vitro, in resolving skin blisters in vivo, and after cardiopulmonary bypass surgery.Circ Res20049411912614656926KNakaiTOhtaISakumaInhibition of endothelium-dependent relaxation by hemoglobin in rabbit aortic strips: comparison between acellular hemoglobin derivatives and cellular hemoglobins.J Cardiovasc Pharmacol1996281151238797145CDReiterXWangJETanus-SantosCell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease.Nat Med200281383138912426562MTGladwinJRLancasterBAFreemanANSchechterNitric oxide’s reactions with hemoglobin: a view through the SNO-storm.Nat Med2003949650012724752MRLangloisJRDelangheBiological and clinical significance of haptoglobin polymorphism in humans.Clin Chem199642158916008855140RCHartmannDEJenkinsJrLCMcKeeRMHeysselParoxysmal nocturnal hemoglobinuria: clinical and laboratory studies relating to iron metabolism and therapy with androgen and iron.Medicine1966453313635975900HNNaumannLWDiggsLBarrerasBJWilliamsPlasma hemoglobin and hemoglobin fractions in sickle cell crisis.Am J Clin Pathol1971561371475567718UPohlDLamontagneImpaired tissue perfusion after inhibition of endothelium-derived nitric oxide.Basic Res Cardiol199186(suppl 2)971051953621RTEberhardtLMcMahonSJDuffySickle cell anemia is associated with reduced nitric oxide bioactivity in peripheral conduit and resistance vessels.Am J Hematol20037410411114508796KANathVShahJJHaggardMechanisms of vascular instability in a transgenic mouse model of sickle cell disease.Am J Physiol Regul Integr Comp Physiol2000279R1949R195511080057DKKaulXDLiuMEFabryRLNagelImpaired nitric oxide-mediated vasodilation in transgenic sickle mouse.Am J Physiol Heart Circ Physiol2000278H1799H180610843875DKKaulXDLiuHYChangRLNagelMEFabryEffect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice.J Clin Invest20041141136114515489961MTGladwinANSchechterFPOgnibeneDivergent nitric oxide bioavailability in men and women with sickle cell disease.Circulation200310727127812538427JJSchnogEHJagerFPvan der DijsEvidence for a metabolic shift of arginine metabolism in sickle cell disease.Ann Hematol20048337137515054669CRMorrisSMMorrisJrWHagarArginine therapy: a new treatment for pulmonary hypertension in sickle cell disease?Am J Respir Crit Care Med2003168636912626350EAziziYDrorKWallisArginase activity in erythrocytes of healthy and ill children.Clin Chim Acta1970283913965450162JRHessVWMacDonaldWWBrinkleySystemic and pulmonary hypertension after resuscitation with cell-free hemoglobin.J Appl Physiol199374176917788514695RLeeKNeyaTASvizzeroGJVlahakesLimitations of the efficacy of hemoglobin-based oxygen-carrying solutions.J Appl Physiol1995792362427559226LFde FigueiredoMMathruDSolankiVWMacDonaldJHessGCKramerPulmonary hypertension and systemic vasoconstriction may offset the benefits of acellular hemoglobin blood substitutes.J Trauma1997428478549191666WMVogelRCDennisGCassidyCSApsteinCRValeriCoronary constrictor effect of stroma-free hemoglobin solutions.Am J Physiol1986251H413H4203740293JAUlatowskiTNishikawaBMatheson-UrbaitisEBucciRJTraystmanRCKoehlerRegional blood flow alterations after bovine fumaryl beta beta-crosslinked hemoglobin transfusion and nitric oxide synthase inhibition.Crit Care Med1996245585658612404EPSloanMKoenigsbergDGensDiaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial.JAMA19992821857186410573278DAClarkSAButlerVBrarenRCHartmannDEJenkinsJrThe kidneys in paroxysmal nocturnal hemoglobinuria.Blood19815783897448417WFRosseParoxysmal nocturnal hemoglobinuria.In: Hoffman R, Benz EJ Jr, Shattil SJ, et al. Hematology: Basic Principles and Practice.3rd ed. New York, NY: Churchill Livingstone; 2000:331-342MHGaultSDuffettLPurchaseJMurphyHemodialysis intravascular hemolysis and kinked blood lines.Nephron1992622672711436336DPHirschRHHollowayGNTytgatGEBoeckxstaensInvolvement of nitric oxide in human transient lower esophageal sphincter relaxations and esophageal primary peristalsis.Gastroenterology1998115137413809834264AJEhererISchwetzHFHammerEffect of sildenafil on oesophageal motor function in healthy subjects and patients with oesophageal motor disorders.Gut20025075876412010875MBortolottiNPandolfoMGiovanniniCMariMMiglioliEffect of sildenafil on hypertensive lower oesophageal sphincter.Eur J Clin Invest20023268268512486868SLNorrisCJohnsonLJHaywoodLeft ventricular filling pressure in sickle cell anemia.J Assoc Acad Minor Phys1992320231576456LLSuttonOCastroDJCrossJESpencerJFLewisPulmonary hypertension in sickle cell disease.Am J Cardiol1994746266288074054MOAdedejiJCespedesKAllenCSubramonyMDHughsonPulmonary thrombotic arteriopathy in patients with sickle cell disease.Arch Pathol Lab Med20011251436144111697998OCastroMHoqueBDBrownPulmonary hypertension in sickle cell disease: cardiac catheterization results and survival.Blood20031011257126112393669EPVichinskyPulmonary hypertension in sickle cell disease.N Engl J Med200435085785914985481DGrisaruEARachmilewitzMMosseriCardiopulmonary assessment in beta-thalassemia major.Chest199098113811422225958ZDDuNRoguinEMilgramKSaabAKorenPulmonary hypertension in patients with thalassemia major.Am Heart J19971345325379327712AAessoposDFarmakisMKaragiorgaCardiac involvement in thalassemia intermedia: a multicenter study.Blood2001973411341611369631EZakynthinosTVassilakopoulosPKaltsasPulmonary hypertension, interstitial lung fibrosis, and lung iron deposition in thalassaemia major.Thorax20015673773911514697GHahalisASManolisDApostolopoulosDAlexopoulosAGVagenakisNCZoumbosRight ventricular cardiomyopathy in beta-thalassaemia major.Eur Heart J20022314715611785997RLitteraGLa NasaGDerchiMDCappelliniCYChangLContuLong-term treatment with sildenafil in a thalassemic patient with pulmonary hypertension.Blood20021001516151712184280VAtichartakarnKLikittanasombatSChuncharuneePulmonary arterial hypertension in previously splenectomized patients with beta-thalassemic disorders.Int J Hematol20037813914512953808TUchidaTMiyakeMMatsunoFatal pulmonary thromboembolism in a patient with paroxysmal nocturnal hemoglobinuria.Rinsho Ketsueki1998391501529545829PGHellerARGrinbergMLencioniMMMolinaAJRoncoroniPulmonary hypertension in paroxysmal nocturnal hemoglobinuria.Chest19921026426431643968GWStewartJAAmessSWEberThrombo-embolic disease after splenectomy for hereditary stomatocytosis.Br J Haematol1996933033108639421DVerresenWDe BackerJVan MeerbeeckINeetensEVan MarckPVermeireSpherocytosis and pulmonary hypertension coincidental occurrence or causal relationship?Eur Respir J199146296311936235JEHayag-BarinRESmithFCTuckerJrHereditary spherocytosis, thrombocytosis, and chronic pulmonary emboli: a case report and review of the literature.Am J Hematol19985782849423823BMuraliADrainDSellerJDunningAVuylstekePulmonary thromboendarterectomy in a case of hereditary stomatocytosis.Br J Anaesth20039173974114570800DLJardineADLaingDelayed pulmonary hypertension following splenectomy for congenital spherocytosis.Intern Med J20043421421615086707XJaisSJTillTCynoberAn extreme consequence of splenectomy in dehydrated hereditary stomatocytosis: gradual thrombo-embolic pulmonary hypertension and lung-heart transplantation.Hemoglobin20032713914712908798IDStuardRSHeusinkveldAJMossMicroangiopathic hemolytic anemia and thrombocytopenia in primary pulmonary hypertension.N Engl J Med19722878698705071968JTMcCarthyBAStaatsPulmonary hypertension, hemolytic anemia, and renal failure: a mitomycin-associated syndrome.Chest1986896086113082608SJJubelirerPrimary pulmonary hypertension: its association with microangiopathic hemolytic anemia and thrombocytopenia.Arch Intern Med1991151122112232043024RGGeisslerAGanserKHubnerGHorDHoelzer47-year-old patient with pulmonary hypertension, anemia and thrombocytopenia.Internist (Berl)1995363853887775089HSuzukiMNakasatoSSatoMicroangiopathic hemolytic anemia and thrombocytopenia in a child with atrial septal defect and pulmonary hypertension.Tohoku J Exp Med19971813793849163853PLabruneJZittounIDuvaltierHaemolytic uraemic syndrome and pulmonary hypertension in a patient with methionine synthase deficiency.Eur J Pediatr199915873473910485306EGFischerJMMarekAMorrisMBNashelskyCholesterol granulomas of the lungs associated with microangiopathic hemolytic anemia and thrombocytopenia in pulmonary hypertension.Arch Pathol Lab Med20001241813181511100063RChouTGDeLougheryRecurrent thromboembolic disease following splenectomy for pyruvate kinase deficiency.Am J Hematol20016719719911391719RPHebbelAuto-oxidation and a membrane-associated “Fenton reagent”: a possible explanation for development of membrane lesions in sickle erythrocytes.Clin Haematol1985141291402985310SMSadrzadehEGrafSSPanterPEHallawayJWEatonHemoglobin: a biologic fenton reagent.J Biol Chem198425914354143566094553EAManciDECulbersonYMYangCauses of death in sickle cell disease: an autopsy study.Br J Haematol200312335936514531921MLJisonMTGladwinHemolytic anemia-associated pulmonary hypertension of sickle cell disease and the nitric oxide/arginine pathway.Am J Respir Crit Care Med20031683412826592CSSimionattoRCabalRLJonesRAGalbraithThrombophlebitis and disturbed hemostasis following administration of intravenous hematin in normal volunteers.Am J Med1988855385403177402JDStudtJAHovingaGAntoineFatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin.Blood200510554254415367436MWRadomskiRMPalmerSMoncadaThe anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide.Br J Pharmacol1987926396463322462ILMegsonNSogoFAMazzeiARButlerJCWaltonDJWebbInhibition of human platelet aggregation by a novel S-nitrosothiol is abolished by haemoglobin and red blood cells in vitro: implications for anti-thrombotic therapy.Br J Pharmacol20001311391139811090112MJBroekmanAMEiroaAJMarcusInhibition of human platelet reactivity by endothelium-derived relaxing factor from human umbilical vein endothelial cells in suspension: blockade of aggregation and secretion by an aspirin-insensitive mechanism.Blood199178103310401868238MVCataniFBernassolaARossiGMelinoInhibition of clotting factor XIII activity by nitric oxide.Biochem Biophys Res Commun19982492752789705871JShaoTMiyataKYamadaProtective role of nitric oxide in a model of thrombotic microangiopathy in rats.J Am Soc Nephrol2001122088209711562407YKayanokiSKawataEYamasakiReduced nitric oxide production by L-arginine deficiency in lysinuric protein intolerance exacerbates intravascular coagulation.Metabolism1999481136114010484053SABallardCJGingellKTangLATurnerMEPriceAMNaylorEffects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes.J Urol1998159216421719598563JDCorbinSHFrancisDJWebbPhosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.Urology20026041112414329AVGraca-SouzaMAArrudaMSde FreitasCBarja-FidalgoPLOliveiraNeutrophil activation by heme: implications for inflammatory processes.Blood2002994160416512010821FAWagenerEFeldmanTde WitteNGAbrahamHeme induces the expression of adhesion molecules ICAM-1, VCAM-1, and E selectin in vascular endothelial cells.Proc Soc Exp Biol Med19972164564639402154LPBignoldImportance of platelets in increased vascular permeability evoked by experimental haemarthrosis in synovium of the rat.Pathology1980121691797413251MXueMRDel BigioIntracerebral injection of autologous whole blood in rats: time course of inflammation and cell death.Neurosci Lett200028323023210754230RDe CaterinaPLibbyHBPengNitric oxide decreases cytokine-induced endothelial activation: nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines.J Clin Invest19959660687542286MSKannanSGuiangDEJohnsonNitric oxide: biological role and clinical uses.Indian J Pediatr19986533334510771982JTakedaTMiyataKKawagoeDeficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria.Cell1993737037118500164MBesslerPJMasonPHillmenParoxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene.EMBO J1994131101178306954MHHolguinLRFredrickNJBernshawLAWilcoxCJParkerIsolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria.J Clin Invest1989847172738160FVan LenteAMarchandRSGalenDiagnosis of hemolytic disease by electrophoresis of erythrocyte lactate dehydrogenase isoenzymes on cellulose acetate or Agarose.Clin Chem198127145314557273410RRavelFactor deficiency anemia.In: Clinical Laboratory Medicine: Clinical Applications of Laboratory Data. 6th ed. St Louis, Mo: Mosby-Year Book; 1995:29-30PHillmenCHallJCMarshEffect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.N Engl J Med200435055255914762182RLPaquetteRYoshimuraCVeisehLKunkelJGajewskiPJRosenClinical characteristics predict response to antithymocyte globulin in paroxysmal nocturnal haemoglobinuria.Br J Haematol19979692979012693RRavelDepletion anemia.In: Clinical Laboratory Medicine: Clinical Applications of Laboratory Data. 6th ed. St Louis, Mo: Mosby-Year Book; 1995:54HRubinParoxysmal nocturnal hemoglobinuria with renal failure.JAMA19712154334365107387DVallaDDhumeauxGBabanyHepatic vein thrombosis in paroxysmal nocturnal hemoglobinuria: a spectrum from asymptomatic occlusion of hepatic venules to fatal Budd-Chiari syndrome.Gastroenterology1987935695753609666PHillmenSMLewisMBesslerLLuzzattoJVDacieNatural history of paroxysmal nocturnal hemoglobinuria.N Engl J Med1995333125312587566002CHallSRichardsPHillmenPrimary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH).Blood20031023587359112893760TWiedmerSEHallTLOrtelWHKaneWFRossePJSimsComplement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria.Blood199382119211967688991PJSimsSARollinsTWiedmerRegulatory control of complement on blood platelets: modulation of platelet procoagulant responses by a membrane inhibitor of the C5b-9 complex.J Biol Chem198926419228192352808422AHillMElebuteJCMarshSustained control of hemolysis and symptoms and reduced transfusion requirements over a period of 2 years in paroxysmal nocturnal hemoglobinuria (PNH) with eculizumab therapy.Blood2004104772a
TI - The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma Hemoglobin
JO - JAMA
DO - 10.1001/jama.293.13.1653
DA - 2005-04-06
UR - https://www.deepdyve.com/lp/american-medical-association/the-clinical-sequelae-of-intravascular-hemolysis-and-extracellular-GpCg0ONnJ5
SP - 1653
EP - 1662
VL - 293
IS - 13
DP - DeepDyve
ER -